Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Critical Reviews in Oral Biology & Medicine
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Devaraj, K.
Right arrow Articles by Wu, T.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
14(5):345-362 (2003)     Crit Rev Oral Biol Med
© 2003 International and American Associations for Dental Research

DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA

Kalpana Devaraj1,4, Maura L. Gillison2 and T.-C. Wu1,2,3,4,*

1 Departments of Pathology,
2 Oncology,
3 Obstetrics and Gynecology, and
4 Molecular Microbiology and Immunology, The Johns Hopkins Medical Institutions, 720 Rutland Avenue, Ross Building 512, Baltimore, MD 21205, USA;

Correspondence: * corresponding author, wutc{at}jhmi.edu

High-risk genotypes of the human papillomavirus (HPV), particularly HPV type 16, are found in a distinct subset of head and neck squamous cell carcinomas (HNSCC). Thus, these HPV-associated HNSCC may be prevented or treated by vaccines designed to induce appropriate HPV virus-specific immune responses. Infection by HPV may be prevented by neutralizing antibodies specific for the viral capsid proteins. In clinical trials, vaccines comprised of HPV virus-like particles (VLPs) have shown great promise as prophylactic HPV vaccines. However, given that capsid proteins are not expressed at detectable levels by infected basal keratinocytes, vaccines with therapeutic potential must target other non-structural viral antigens. Two HPV oncogenic proteins, E6 and E7, are important in the induction and maintenance of cellular transformation and are co-expressed in the majority of HPV-containing carcinomas. Therefore, therapeutic vaccines targeting these proteins may have potential to control HPV-associated malignancies. Various candidate therapeutic HPV vaccines are currently being tested whereby E6 and/or E7 is administered in live vectors, in peptides or protein, in nucleic acid form, as components of chimeric VLPs, or in cell-based vaccines. Encouraging results from experimental vaccination systems in animal models have led to several prophylactic and therapeutic vaccine clinical trials. Should they fulfill their promise, these vaccines may prevent HPV infection or control its potentially life-threatening consequences in humans.

Key Words: HPV vaccines • head and neck squamous cell carcinoma • immunotherapy • tumor-specific antigens • cytotoxic T-lymphocyte • tumor immunology

Critical Reviews in Oral Biology & Medicine, Vol. 14, No. 5, 345-362 (2003)
DOI: 10.1177/154411130301400505
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. M. Smith, L. M. Rubenstein, J. M. Ritchie, J. H. Lee, T. H. Haugen, E. Hamsikova, and L. P. Turek
Does Pretreatment Seropositivity to Human Papillomavirus Have Prognostic Significance for Head and Neck Cancers?
Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2087 - 2096.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
H. Liu, B. H. Wu, G. J. Rowse, and P. C. R. Emtage
Induction of CD4-Independent E7-Specific CD8+ Memory Response by Heat Shock Fusion Protein
Clin. Vaccine Immunol., August 1, 2007; 14(8): 1013 - 1023.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C E Anderson, K M McLaren, F Rae, R J Sanderson, and K S Cuschieri
Human papilloma virus in squamous carcinoma of the head and neck: a study of cases in south east Scotland
J. Clin. Pathol., April 1, 2007; 60(4): 439 - 441.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. H. Kang, J. H. Lee, C. K. Song, H. D. Han, B. C. Shin, S. I. Pai, C.-F. Hung, C. Trimble, J.-S. Lim, T. W. Kim, et al.
Epigallocatechin-3-Gallate Enhances CD8+ T Cell-Mediated Antitumor Immunity Induced by DNA Vaccination
Cancer Res., January 15, 2007; 67(2): 802 - 811.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
B Perez-Ordonez, M Beauchemin, and R C K Jordan
Molecular biology of squamous cell carcinoma of the head and neck.
J. Clin. Pathol., May 1, 2006; 59(5): 445 - 453.
[Abstract] [Full Text] [PDF]